Noxopharm Ltd has released a press release.
Extension of Convertible Notes and Funding
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- HERACLES clinical trial Update 4
- Appendix 4E Preliminary Final Report
- HERACLES clinical trial Update 3
- HERACLES clinical trial Update 2
- US company demonstrates strong Sofra potential
Later from Noxopharm
- First US patent for Sofra technology platform
- September 2025 Quarterly Activities Report and Appendix 4C
- Second part of HERACLES clinical trial begins
- First dose in HERACLES clinical trial Part Two
- HERACLES clinical trial Update 5
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm